See also this year's filing and all EDGAR filings for this company.
PDF Report 0000744218_2014_Celldex_Therapeutics_Inc.pdf
Logs
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS': 12, '0021 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2)': 3}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000744218, Celldex Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 6,950,000 |
| 1 | LiabilitiesCurrent | 20,350,000 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 305,189,000 |
| 4 | AssetsNoncurrent | 148,000 |
| 5 | PropertyPlantAndEquipmentNet | 9,973,000 |
| 6 | Goodwill | 31,785,000 |
| 7 | remainder_Assets | 0 |
| 8 | GeneralAndAdministrativeExpense | 14,805,000 |
| 9 | ResearchAndDevelopmentExpense | 67,401,000 |
| 10 | remainder_Expenses | 3,347,000 |
| 11 | remainder_Revenues | 4,111,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | -185,000 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 27,300,000 |
| 1 | Assets | 347,095,000 |
| 2 | Expenses | 85,553,000 |
| 3 | Revenues | 4,111,000 |
| 4 | StockholdersEquity | 319,795,000 |
| 5 | NetIncome | -81,442,000 |
| 6 | ComprehensiveNetIncome | -81,534,500 |
| 7 | BaseVar | 232,122,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.90 |
| 9 | EconomicCapitalRatio | 2.28 |
Edgar->Model Mapping
Feature Distribution
Change over Time
